CFO Myszkowski sells 45,167 shares for $893,095.40 across 4 trades (Jan 6–7); stock down 50.2% from 52-week high
Kenneth Allen Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, executed 4 separate sales totaling 45,167 shares for $893,095.40 at blended average price $19.77 on January 6–7, 2025, reducing his holdings by 9.0% to 455,433 shares. The timing of these sales is notable: the stock has declined 50.2% from its 52-week high of $39.48 and is down 16.7% over the prior 30 days, yet the CFO's trade prices averaged $19.77 versus the current price of $19.67. More significantly, across his 5 prior open-market sales at Arrowhead, Myszkowski achieved a 100% well-timed rate at the 90-day horizon—all five prior sales were followed by stock declines, with 90-day returns ranging from -1.0% to -28.1%. The company backdrop is material: latest quarterly revenue was $0.00 with annual revenue declining 98.5%, and the company reported a net loss of $-170,793,000.00 for its most recent full fiscal year. This sale pattern—consistent with the insider's prior execution discipline at this ticker—occurs when the stock is substantially depressed but the company's operational fundamentals remain deeply challenged.